» Articles » PMID: 34708574

A Bridge Too Far? Real-World Practice Patterns of Early Glucocorticoid Use in the Canadian Early Arthritis Cohort

Abstract

Objective: To describe patterns of glucocorticoid use in a large real-world cohort with early rheumatoid arthritis (RA) and assess the impact on disease activity and treatment.

Methods: Data are from adults with new RA (≤1 year) recruited to the Canadian Early Arthritis Cohort (CATCH) and are stratified on the basis of whether a person was prescribed oral glucocorticoids within 3 months of study entry. Disease activity was compared over 24 months. Mixed-effects logistic regression was used for adjusted odds ratios (aORs) of escalation to biologics separately for 12 and 24 months, with random effects terms to account for prescribing patterns clustering by study site.

Results: Among 1891 persons, 30% received oral steroids. Users were older, were less often employed, and had shorter disease duration and higher disease activity. Disease activity improved over time, with early glucocorticoid users starting at higher levels of disease activity. Participants with early oral glucocorticoids were more likely to be on a biologic at 12 months (aOR = 2.4; 95% confidence interval [CI], 1.5-3.7) and 24 months (aOR = 1.9; 95% CI, 1.3-3.0). Despite Canadian clinical practice guidelines to limit corticosteroid use to short-term or 'bridge' therapy, 30% of patients who used oral glucocorticoids still used them 2 years later.

Conclusion: Early steroids were prescribed sparingly in CATCH and were often indicative of more active baseline disease as well as the need for progression to biologics.

Citing Articles

Osteoporosis and fracture risk are multifactorial in patients with inflammatory rheumatic diseases.

Buttgereit F, Palmowski A, Bond M, Adami G, Dejaco C Nat Rev Rheumatol. 2024; 20(7):417-431.

PMID: 38831028 DOI: 10.1038/s41584-024-01120-w.


Sex and age do not modify the association between glucocorticoids and bone mineral density in patients with rheumatoid arthritis: a cross-sectional study.

Palmowski A, Boyadzhieva Z, Nielsen S, Muche B, Hermann S, Boers M Arthritis Res Ther. 2023; 25(1):98.

PMID: 37287080 PMC: 10246103. DOI: 10.1186/s13075-023-03083-x.

References
1.
Smolen J, Breedveld F, Burmester G, Bykerk V, Dougados M, Emery P . Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2015; 75(1):3-15. PMC: 4717393. DOI: 10.1136/annrheumdis-2015-207524. View

2.
Svensson B, Boonen A, Albertsson K, van der Heijde D, Keller C, Hafstrom I . Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial. Arthritis Rheum. 2005; 52(11):3360-70. DOI: 10.1002/art.21298. View

3.
Morrison E, Capell H . Corticosteroids in the management of early and established rheumatoid disease. Rheumatology (Oxford). 2006; 45(9):1058-61. DOI: 10.1093/rheumatology/kel230. View

4.
Listing J, Gerhold K, Zink A . The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatology (Oxford). 2012; 52(1):53-61. DOI: 10.1093/rheumatology/kes305. View

5.
Bykerk V . Low-dose Glucocorticoid Use Does Not Reduce Biologic Use in Early RA, Nor Do Biologics Reduce the Need for Glucocorticoids. J Rheumatol. 2019; 46(4):331-332. DOI: 10.3899/jrheum.181262. View